Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed ...

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to ...

The VERONA trial showed no significant overall survival improvement with Venclexta plus azacitidine in intermediate/high-risk MDS patients compared to placebo. The combination arm demonstrated higher ...

ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...

Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...

Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...

The appraisal committee considered evidence submitted by Celgene and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

Am J Health Syst Pharm. 2005;62(15):1567-1573. Routine monitoring for efficacy and toxicity should be performed. Renal and hepatic function, quality of life, and adverse effects should be monitored.

Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders in which immature stem cells do not mature to become red blood cells, white blood cells or platelets. Patients with ...

The alternative text for this image may have been generated using AI. To the best of our knowledge, our two cases are the first reported cases that showed a very good response to 5-azacitidine in the ...